文献速递心脑血管急症重症综合管理与镇静镇痛

经导管主动脉瓣植入联合血流储备分数指导的经皮冠状动脉介入治疗与常规外科主动脉瓣置换联合冠状动脉旁路移植术治疗主动脉瓣狭窄合并复杂或多支冠状动脉病变(TCW):一项国际、多中心、前瞻性、开放标签、非劣效性、随机对照试验

TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and complex or multivessel coronary disease (TCW): an international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial.
PubMed 文献 · Lancet · 2024-12-04
一句话结论在≥70岁重度主动脉瓣狭窄合并复杂冠心病患者中,FFR指导的PCI+TAVI在1年复合终点上非劣于且优于SAVR+CABG,主要由全因死亡和致死性出血减少驱动。

TCW试验为国际、多中心、前瞻性、开放标签、非劣效性随机对照试验,纳入172例≥70岁重度主动脉瓣狭窄合并复杂冠心病患者,1:1随机至FFR指导的PCI+TAVI组(91例)或SAVR+CABG组(81例)。主要终点为1年全因死亡、心肌梗死、致残性卒中、临床驱动的靶血管血运重建、瓣膜再干预及致死性或致残性出血的复合终点。FFR指导的PCI+TAVI组主要终点事件4%(4/91),SAVR+CABG组23%(17/77),风险差-18.5(90% CI -27.8至-9.7),低于预设15%非劣效界值(p非劣效<0.001),且优效性检验显示FFR指导的PCI+TAVI优于SAVR+CABG(HR 0.17,95% CI 0.06-0.51;p优效<0.001)。该优势主要由全因死亡(0% vs 10%,p=0.0025)和致死性出血(2% vs 12%,p=0.010)驱动。

要点

  • 在≥70岁重度主动脉瓣狭窄合并复杂冠心病患者中,FFR指导的PCI+TAVI组1年主要复合终点事件4%(4/91),SAVR+CABG组23%(17/77),风险差-18.5(90% CI -27.8至-9.7),低于15%非劣效界值(p非劣效<0.001)。
  • FFR指导的PCI+TAVI较SAVR+CABG显著降低主要复合终点(HR 0.17,95% CI 0.06-0.51;p优效<0.001)。
  • 全因死亡:FFR指导的PCI+TAVI组0%(0/91)vs SAVR+CABG组10%(7/77),p=0.0025。
  • 致死性出血:FFR指导的PCI+TAVI组2%(2/91)vs SAVR+CABG组12%(9/77),p=0.010。
  • TCW试验是首个在重度主动脉瓣狭窄合并复杂冠心病患者中比较经皮与外科治疗的试验,经皮治疗显示有利的主要终点和死亡结局。

适用人群与场景

  • 年龄≥70岁、重度主动脉瓣狭窄合并复杂冠状动脉病变、经现场心脏团队评估认为经皮或外科治疗均可行的患者。

研究设计与关键结果

  • 国际、多中心、前瞻性、开放标签、非劣效性随机对照试验,在欧洲18家三级医疗中心开展;2018年5月31日至2023年6月30日纳入172例患者,FFR指导的PCI+TAVI组91例,SAVR+CABG组81例;平均年龄76.5岁(SD 3.9),男性118例(69%),女性54例(31%)。
  • 主要终点为治疗后1年全因死亡、心肌梗死、致残性卒中、临床驱动的靶血管血运重建、瓣膜再干预及致死性或致残性出血的复合终点;FFR指导的PCI+TAVI组4%(4/91)vs SAVR+CABG组23%(17/77),风险差-18.5(90% CI -27.8至-9.7),低于预设15%非劣效界值(p非劣效<0.001)。
  • 优效性检验:FFR指导的PCI+TAVI优于SAVR+CABG(HR 0.17,95% CI 0.06-0.51;p优效<0.001)。
  • 全因死亡:FFR指导的PCI+TAVI组0%(0/91)vs SAVR+CABG组10%(7/77),p=0.0025。
  • 致死性出血:FFR指导的PCI+TAVI组2%(2/91)vs SAVR+CABG组12%(9/77),p=0.010。

证据类型、等级与局限

  • 证据类型:国际、多中心、前瞻性、开放标签、非劣效性随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在≥70岁重度主动脉瓣狭窄合并复杂冠心病、经心脏团队评估经皮或外科治疗均可行的患者中,FFR指导的PCI+TAVI较SAVR+CABG显著降低1年主要复合终点事件(4% vs 23%)、全因死亡(0% vs 10%)和致死性出血(2% vs 12%)。
  • TCW试验是首个在重度主动脉瓣狭窄合并复杂冠心病患者中比较经皮与外科治疗的试验,显示经皮治疗有利的主要终点和死亡结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with severe aortic stenosis present frequently (∼50%) with concomitant obstructive coronary artery disease. Current guidelines recommend combined surgical aortic valve replacement (SAVR) and coronary artery bypass grafting (CABG) as the preferred treatment. Transcatheter aortic valve implantation (TAVI) and fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) represent a valid treatment alternative. We aimed to test the non-inferiority of FFR-guided PCI plus TAVI versus SAVR plus CABG in patients with severe aortic stenosis and complex coronary artery disease.

METHODS: This international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial was conducted at 18 tertiary medical centres across Europe. Patients (aged ≥70 years) with severe aortic stenosis and complex coronary artery disease, deemed feasible for percutaneous or surgical treatment according to the on-site Heart Team, were randomly assigned (1:1) to FFR-guided PCI plus TAVI or SAVR plus CABG according to a computer-generated sequence with random permuted blocks sizes stratified by site. The primary endpoint was a composite of all-cause mortality, myocardial infarction, disabling stroke, clinically driven target-vessel revascularisation, valve reintervention, and life-threatening or disabling bleeding at 1 year post-treatment. The trial was powered for non-inferiority (with a margin of 15%) and if met, for superiority. The primary and safety analyses were done per an intention-to-treat principle. This trial is registered with ClinicalTrials.gov (NCT03424941) and is closed.

FINDINGS: Between May 31, 2018, and June 30, 2023, 172 patients were enrolled, of whom 91 were assigned to the FFR-guided PCI plus TAVI group and 81 to the SAVR plus CABG group. The mean age of patients was 76·5 years (SD 3·9). 118 (69%) of 172 patients were male and 54 (31%) patients were female. FFR-guided PCI plus TAVI resulted in favourable outcomes for the primary endpoint (four [4%] of 91 patients) versus SAVR plus CABG (17 [23%] of 77 patients; risk difference -18·5 [90% CI -27·8 to -9·7]), which was below the 15% prespecified non-inferiority margin (pnon-inferiority<0·001). FFR-guided PCI plus TAVI was superior to SAVR plus CABG (hazard ratio 0·17 [95% CI 0·06-0·51]; psuperiority<0·001), which was driven mainly by all-cause mortality (none [0%] of 91 patients vs seven (10%) of 77 patients; p=0·0025) and life-threatening bleeding (two [2%] vs nine [12%]; p=0·010).

INTERPRETATION: The TCW trial is the first trial to compare percutaneous treatment versus surgical treatment in patients with severe aortic stenosis and complex coronary artery disease, showing favourable primary endpoint and mortality outcomes with percutaneous treatment.

FUNDING: Isala Heart Centre and Medtronic.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Kedhi E, Hermanides RS, Dambrink JE, et al. TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and complex or multivessel coronary disease (TCW): an international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial. Lancet. 2024. PMID: 39644913. doi:10.1016/S0140-6736(24)02100-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。